110 related articles for article (PubMed ID: 14605998)
1. The effects of K-111, a new insulin-sensitizer, on metabolic syndrome in obese prediabetic rhesus monkeys.
Bodkin NL; Pill J; Meyer K; Hansen BC
Horm Metab Res; 2003 Oct; 35(10):617-24. PubMed ID: 14605998
[TBL] [Abstract][Full Text] [Related]
2. A novel peroxisome proliferator--activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys.
Ding SY; Tigno XT; Braileanu GT; Ito K; Hansen BC
Metabolism; 2007 Oct; 56(10):1334-9. PubMed ID: 17884441
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and morphological effects of K-111, a peroxisome proliferator-activated receptor (PPAR)alpha activator, in non-human primates.
Schäfer SA; Hansen BC; Völkl A; Fahimi HD; Pill J
Biochem Pharmacol; 2004 Jul; 68(2):239-51. PubMed ID: 15193996
[TBL] [Abstract][Full Text] [Related]
4. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice.
Verreth W; De Keyzer D; Pelat M; Verhamme P; Ganame J; Bielicki JK; Mertens A; Quarck R; Benhabilès N; Marguerie G; Mackness B; Mackness M; Ninio E; Herregods MC; Balligand JL; Holvoet P
Circulation; 2004 Nov; 110(20):3259-69. PubMed ID: 15533870
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic actions of an insulin receptor activator and a novel peroxisome proliferator-activated receptor gamma agonist in the spontaneously hypertensive obese rat model of metabolic syndrome X.
Velliquette RA; Friedman JE; Shao J; Zhang BB; Ernsberger P
J Pharmacol Exp Ther; 2005 Jul; 314(1):422-30. PubMed ID: 15833894
[TBL] [Abstract][Full Text] [Related]
6. Fluid compartmental shifts with efficacious pioglitazone therapy in overweight monkeys: implications for peroxisome proliferator-activated receptor-gamma agonist use in prediabetes.
Kavanagh K; Brown KK; Berquist ML; Zhang L; Wagner JD
Metabolism; 2010 Jun; 59(6):914-20. PubMed ID: 20197197
[TBL] [Abstract][Full Text] [Related]
7. Degradation in insulin sensitivity with increasing severity of the metabolic syndrome in obese postmenopausal women.
Karelis AD; Henry JF; St-Pierre DH; Prud'homme D; Rabasa-Lhoret R
Diabetes Obes Metab; 2006 May; 8(3):336-41. PubMed ID: 16634994
[TBL] [Abstract][Full Text] [Related]
8. Treatment of metabolic syndrome.
Wagh A; Stone NJ
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):213-28. PubMed ID: 15151470
[TBL] [Abstract][Full Text] [Related]
9. Weight loss improves heart rate recovery in overweight and obese men with features of the metabolic syndrome.
Brinkworth GD; Noakes M; Buckley JD; Clifton PM
Am Heart J; 2006 Oct; 152(4):693.e1-6. PubMed ID: 16996838
[TBL] [Abstract][Full Text] [Related]
10. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats.
Rivera L; Morón R; Sánchez M; Zarzuelo A; Galisteo M
Obesity (Silver Spring); 2008 Sep; 16(9):2081-7. PubMed ID: 18551111
[TBL] [Abstract][Full Text] [Related]
11. Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome.
Tzotzas T; Samara M; Constantinidis T; Tziomalos K; Krassas G
Angiology; 2007; 58(1):26-33. PubMed ID: 17351155
[TBL] [Abstract][Full Text] [Related]
12. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes.
Mojiminiyi OA; Abdella NA; Al Arouj M; Ben Nakhi A
Int J Obes (Lond); 2007 Feb; 31(2):213-20. PubMed ID: 16755284
[TBL] [Abstract][Full Text] [Related]
13. The triglyceride/HDL-cholesterol ratio as a marker of cardiovascular risk in obese children; association with traditional and emergent risk factors.
Quijada Z; Paoli M; Zerpa Y; Camacho N; Cichetti R; Villarroel V; Arata-Bellabarba G; Lanes R
Pediatr Diabetes; 2008 Oct; 9(5):464-71. PubMed ID: 18507788
[TBL] [Abstract][Full Text] [Related]
14. Insulin sensitivity indices of glucose and free fatty acid metabolism in obese children and adolescents in relation to serum lipids.
Reinehr T; Kiess W; Andler W
Metabolism; 2005 Mar; 54(3):397-402. PubMed ID: 15736120
[TBL] [Abstract][Full Text] [Related]
15. Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome.
Zwirska-Korczala K; Konturek SJ; Sodowski M; Wylezol M; Kuka D; Sowa P; Adamczyk-Sowa M; Kukla M; Berdowska A; Rehfeld JF; Bielanski W; Brzozowski T
J Physiol Pharmacol; 2007 Mar; 58 Suppl 1():13-35. PubMed ID: 17443025
[TBL] [Abstract][Full Text] [Related]
16. Insulin resistance, beta-cell function, and glucose tolerance in Brazilian adolescents with obesity or risk factors for type 2 diabetes mellitus.
da Silva RC; Miranda WL; Chacra AR; Dib SA
J Diabetes Complications; 2007; 21(2):84-92. PubMed ID: 17331856
[TBL] [Abstract][Full Text] [Related]
17. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.
Reaven GM
Panminerva Med; 2005 Dec; 47(4):201-10. PubMed ID: 16489319
[TBL] [Abstract][Full Text] [Related]
18. Central obesity, the metabolic syndrome, and plasminogen activator inhibitor-1 in young adults.
Appel SJ; Harrell JS; Davenport ML
J Am Acad Nurse Pract; 2005 Dec; 17(12):535-41. PubMed ID: 16293162
[TBL] [Abstract][Full Text] [Related]
19. Elevated intraocular pressure is associated with insulin resistance and metabolic syndrome.
Oh SW; Lee S; Park C; Kim DJ
Diabetes Metab Res Rev; 2005; 21(5):434-40. PubMed ID: 15651065
[TBL] [Abstract][Full Text] [Related]
20. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome.
Salmenniemi U; Ruotsalainen E; Pihlajamäki J; Vauhkonen I; Kainulainen S; Punnonen K; Vanninen E; Laakso M
Circulation; 2004 Dec; 110(25):3842-8. PubMed ID: 15596567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
